# Baricitinib in the Treatment of Intestinal Behçet's Syndrome

> **NCT06849908** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 56 (estimated)

## Conditions studied

- Behcet Syndrome, Intestinal Type

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT06849908
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06849908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06849908, "Baricitinib in the Treatment of Intestinal Behçet's Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06849908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*